Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (119)

2024

  1. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  2. Quitline nurses' experiences in providing telephone-based smoking cessation help to mental health patients: A mixed methods study

    Journal of Psychiatric and Mental Health Nursing

  3. Toenail zinc and risk of prostate cancer in the MCC-Spain case-control study

    Environmental Research, Vol. 245

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Comparing client and staff reports on tobacco-related knowledge, attitudes, beliefs and services provided in substance use treatment

    Tobacco Induced Diseases, Vol. 21, Núm. March

  3. Compliance with the smoke-free policy in hospitals in Spain: The patients' perspective

    European Journal of Cancer Prevention, Vol. 32, Núm. 1, pp. 81-88

  4. EUREST-RISE: An innovative networking and training project on European Tobacco Control

    Tobacco Prevention and Cessation

  5. Erratum: Comparing client and staff reports on tobaccorelated knowledge, attitudes, beliefs and services provided in substance use treatment (Tobacco Induced Diseases DOI: 10.18332/tid/160974)

    Tobacco Induced Diseases

  6. Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions

    Journal of the National Cancer Institute, Vol. 115, Núm. 6, pp. 712-732

  7. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

  8. Passive exposure and perceptions of smoke-free policies in hospital and university campuses among nursing students: A cross-sectional multicenter study

    Tobacco Induced Diseases, Vol. 21

2022

  1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  2. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  3. Accounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data

    Cancer Epidemiology Biomarkers and Prevention, Vol. 31, Núm. 3, pp. 679-687

  4. Differences in breast cancer-risk factors between screen-detected and non-screen-detected cases (MCC-Spain study)

    Cancer Causes and Control, Vol. 33, Núm. 1, pp. 125-136

  5. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

  6. Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD

    Therapeutic Advances in Hematology, Vol. 13

  7. Toenail zinc as a biomarker: Relationship with sources of environmental exposure and with genetic variability in MCC-Spain study

    Environment International, Vol. 169

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Consumption of ultra-processed food and drinks and chronic lymphocytic leukemia in the mcc-spain study

    International Journal of Environmental Research and Public Health, Vol. 18, Núm. 10